BMS-986012
- Generic Name
- BMS-986012
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1894272-37-7
- Unique Ingredient Identifier
- Q8PK97HY9B
- Background
BMS-986012 is a human antifucosyl-GM1 antibody. It is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).
- Associated Conditions
- -
- Associated Therapies
- -
BMS-986012 With Nivolumab, Chemotherapy Is Promising in ES-SCLC
BMS-986012 plus nivolumab and chemotherapy showed a slight PFS benefit and OS improvement in extensive-stage small cell lung cancer patients compared to nivolumab and chemotherapy alone, according to a phase 2 study interim analysis.
BMS scores with ES-SCLC drug in patients with brain metastases
BMS's BMS-986012 nearly doubled overall survival in ES-SCLC patients with brain metastases in a Phase II trial, with an OS of 16.3 months vs. 8.7 months in the control group. The study compares BMS-986012, Opdivo, and chemotherapy versus Opdivo plus chemotherapy.
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC
BMS-986012 added to nivolumab plus chemotherapy showed modest PFS benefit and OS improvement in ES-SCLC, with a manageable safety profile, according to interim phase 2 CA001-050 study data presented at the 2024 ESMO Congress.
Novel Monoclonal Antibody Combo Shows Modest PFS Benefit in Extensive-Stage SCLC
BMS-986012 plus nivolumab and chemotherapy showed modest PFS and OS benefits in ES-SCLC, with manageable safety profiles, according to interim phase 2 CA001-050 study data presented at ESMO 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath